2017: Preliminary IFRS results
[et_pb_section bb_built=“1″][et_pb_row][et_pb_column type=“4_4″][et_pb_text _builder_version=“3.0.105″ background_layout=“light“ text_font=“Source Sans Pro|300|||||||“]
2017: According to the preliminary IFRS results, increased its
In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of €289,9m (previous year: €275.6m), an operating result (EBIT) of €9.4 (previous year: €13.4m), and an annual net profit of €6.98m (previous year: €10.7m). A capital increase of € 7.4 million improved the equity ratio from 54% (2016) to 58% in 2017.
After the exceptional year 2016, the results stabilized at a high level.
After a cautious start into 2017, the HAEMATO Group made significant gains in the second half of the year and exceeded its expectations of EBIT (EUR 8.28 million), EBITDA (EUR 10.1 million) and net income.
As a supplier of specialty pharmaceuticals, the HAEMATO Group is growing faster than the market. The specialization in medications for the treatment of chronic diseases means that demographic trends will continue to lead to above-average growth in the future.
The addition of the product range to high-margin medical products is being consistently further developed. In December 2017, the first care products based on Hyaluronan were delivered.
The earnings situation allows the Executive Board to propose an unchanged dividend of 30 cents per share to the Supervisory Board.